'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
about
The molecular connections between the cannabinoid system and endometriosisHormonal anticonception anno 2013: a clinician's viewCan platelet indices be new biomarkers for severe endometriosis?Gonadotrophin-releasing hormone analogues and endometriosis: current strategies and new insights.Aromatase inhibitors in post-menopausal endometriosis.Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life.Consensus on current management of endometriosis.Innovations in classical hormonal targets for endometriosis.Association between endometriosis and the interleukin 1A (IL1A) locus.Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signalingTranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis.Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months.Immunological aspects of endometriosis: an update.The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies.Principles of phenomics in endometriosis.Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress.Comparing treatments for endometriosis-related pain symptoms in patients with migraine without aura.Extended regimens of combined hormonal contraception to reduce symptoms related to withdrawal bleeding and the hormone-free interval: a systematic review of randomised and observational studies.Platelets are an unindicted culprit in the development of endometriosis: clinical and experimental evidence.Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.Dienogest in the treatment of endometriosis: systematic review.Reducing low-value care in endometriosis between limited evidence and unresolved issues: a proposal.Challenges in the development of novel therapeutic strategies for treatment of endometriosis.Safety of medical treatments for endometriosis.An overview of early drug development for endometriosis.A systematic review of ultrasonography-guided transvaginal aspiration of recurrent ovarian endometrioma.Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment.Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction.A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg.Beyond Endometriosis Genome-Wide Association Study: From Genomics to Phenomics to the Patient.The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation.Naringenin induces mitochondria-mediated apoptosis and endoplasmic reticulum stress by regulating MAPK and AKT signal transduction pathways in endometriosis cells.From endometriosis to perineal trauma.Time to redefine endometriosis including its pro-fibrotic nature.Medical treatment or surgery for colorectal endometriosis? Results of a shared decision-making approach.The inconvenience due to women's monthly bleeding (ISY) survey: a study of premenstrual symptoms among 5728 women in Europe.Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.Is Shifting to a Progestin Worthwhile When Estrogen-Progestins Are Inefficacious for Endometriosis-Associated Pain?
P2860
Q27005719-665368F0-C0E4-4CE8-81E1-1EB175003A11Q28384050-E85DE690-597C-4DD0-824F-13758AF16E30Q33827128-99E35E31-E7BF-4425-B488-C4DC707FCB0AQ34150249-5D00C58E-8CA5-44CA-90D5-39668CDED229Q34194386-B76BFBE2-FBAB-4A10-83D0-3C3F534D9AA9Q34321877-F5E4C1CF-54EB-44F3-AD11-FBE6428137BFQ34329932-E8432190-86C4-410C-8BD7-48881B896F95Q34335288-28847788-53FC-47AA-AAD5-1A194463CCB6Q34504377-DAF42E5E-DD40-41E7-BD85-BF0FA5B9C51FQ34673135-9A93098B-4FAD-4705-B71C-E6FB6B2932E8Q35107985-521D2182-1A82-46DC-A974-3E3BA149F0DDQ36783498-1E176FE3-C49B-4F94-B841-87800A1DFDCBQ37585132-036F28A6-E529-4B74-B961-3E3F1485A7DDQ37897272-2A207974-12B7-48AC-BEAA-6DEB3FBA5DC3Q37898344-14113453-C13E-4993-ADCA-97505F9E4156Q37988818-4A1AF8E8-905D-42B7-8DC2-D525C2E3DBADQ38006613-133A114F-6CA4-4CFB-858C-F562745A8B1DQ38163041-76F0141E-EFB9-4D24-B31C-5A85DDC58E37Q38223794-462F25AD-DC1C-44F2-A7BB-D63B103722B1Q38300645-5E8F8BE9-0B66-4EC2-84DC-75A80EA4FA21Q38315212-DBF9E982-9840-4EE3-9ADD-DF401A3609DCQ38332570-13E16151-2D84-4501-AC55-5FB917E8813FQ38370004-19765B65-71B6-4F93-A923-D3F15C99C635Q38542606-415B8B3B-5118-409E-A74E-95FC1F9A8560Q38630607-5CA6C83B-86BC-4BA7-BBE4-135AE9B6644CQ38635759-DC5F2227-A31B-426C-9D34-099FC338A99CQ38653393-96F3B168-6EC4-40A1-8BD7-E7B32A226C38Q38796579-8450FAC9-E4B6-4784-B096-926EA47E708BQ38945478-5C00AEF8-2D49-4CB6-A31E-14B3CFF64C48Q39242877-FE1A6096-20C7-43F1-B4E7-770E4A618B54Q39255227-3BF2F4DB-A0E8-41FE-83D8-17E9F3D88A34Q39500666-2B8BA84C-935D-420F-B424-0545BD125B92Q46203957-2AE25470-5822-41F4-9596-DAE76D1401CEQ46264809-5EA4614B-C9D6-426F-BE9B-212435830B53Q46321207-6769AC7A-1119-4ED2-8F2E-1230F95F442CQ47563555-F7DE9140-EB10-4DE5-AC3C-0ABCEA767F2AQ47566630-FACF3B48-050E-482F-B929-A2114D7B4F76Q47788707-3749A4F4-AC7E-4764-8F75-CCC588063302Q48059956-1F281E70-6512-4314-A98F-50E0CC2F8C01Q48305064-43919DCD-8FA0-40CE-8A43-2F0DF7D23E49
P2860
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
@en
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
@nl
type
label
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
@en
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
@nl
prefLabel
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
@en
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
@nl
P2860
P50
P356
P1433
P1476
'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.
@en
P2093
PierGiorgio Crosignani
P2860
P356
10.1093/HUMREP/DEQ302
P407
P577
2010-11-11T00:00:00Z